# Sebastian Pünzeler

> Sebastian Pünzeler is a Series A investor at coparion backing Biotechnology and Health Care. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [coparion](https://shizune.co/investors/profile/coparion)
- Total investments: 4
- Last investment: May 2022
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/spuenzeler

Sebastian Pünzeler is a Series A investor at coparion focused on Biotechnology and Health Care. Sebastian Pünzeler is the Principal at coparion. Sebastian Pünzele attended Ludwig-Maximilians-Universität München.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 75% |
| Health Care | 2 | 50% |
| Life Science | 2 | 50% |
| Therapeutics | 2 | 50% |
| Pharmaceutical | 1 | 25% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 50% |
| Seed | 1 | 25% |
| Series B | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Tubulis | Tubulis is a biotechnology company that develops antibody-drug conjugates (ADCs) for targeted cancer therapy. The company combines proprietary technologies with disease-specific biological insights to create highly stable and effective protein-drug conjugates. Its platform enables the design of ADCs with improved delivery, reduced toxicity, andenhanced therapeutic potential across various cancer types, including solid and hematologic tumors. Tubulis is advancing a pipeline of experimental drug candidates, such as TUB-040 and TUB-030, which are currently being evaluated in clinical settings for cancers like ovarian and lung cancer. The company also collaborates with industry partners and leverages its proprietary conjugation technologies to expand the scope and effectiveness of targeted oncology treatments. | $63.2M | Series B | May 03, 2022 |  |
| Abalos Therapeutics | The company intends to use the funds to advance its arenavirus-based lead candidates towards clinical testing. They will develop the initial product candidates using its proprietary Fast Evolution platform, which will generate virus strains with optimized anti-tumoral properties. These candidates will be selected based on their ability tore-program the immune system to specifically and efficiently eliminate the malignant tumor tissue. | $35.9M | Series A | Oct 14, 2021 |  |
| Tubulis | Tubulis is a biotechnology company that develops antibody-drug conjugates (ADCs) for targeted cancer therapy. The company combines proprietary technologies with disease-specific biological insights to create highly stable and effective protein-drug conjugates. Its platform enables the design of ADCs with improved delivery, reduced toxicity, andenhanced therapeutic potential across various cancer types, including solid and hematologic tumors. Tubulis is advancing a pipeline of experimental drug candidates, such as TUB-040 and TUB-030, which are currently being evaluated in clinical settings for cancers like ovarian and lung cancer. The company also collaborates with industry partners and leverages its proprietary conjugation technologies to expand the scope and effectiveness of targeted oncology treatments. | $12.3M | Series A | Jul 21, 2020 |  |
| Tacalyx | Tacalyx develops therapeutics targeting cancer-specific carbohydrate antigens on the surface of metastatic malignant tumors where no satisfactory treatments exist.The name Tacalyx is derived from TACA (Tumor Associated Carbohydrate Antigen) and ‘lyx’ from the term Glycocalyx, the glycan-containing layer covering cells. Cancer cells differ fromnormal cells by displaying aberrant carbohydrate structures on their surfaces promoting metastasis, angiogenesis or suppression of the immune system. TACAs result from the aberrant glycosylation that is seen with transformation to a tumor cell and represent attractive targets for cancer treatment since they are displayed with high cancer specificity and enhance tumor virulence via the mentioned diverse mechanisms. | $7.4M | Seed | Sep 25, 2019 |  |

4 of 4 investments shown.

## Co-investors
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund, 4 deals together
- [Seventure Partners](https://shizune.co/investors/profile/seventure-partners) — VC Fund, 4 deals together
- [Bayern Kapital](https://shizune.co/investors/profile/bayern-kapital) — VC Fund, 2 deals together
- [BioMedPartners](https://shizune.co/investors/profile/biomedpartners) — VC Fund, 2 deals together
- [Boehringer Ingelheim Venture Fund](https://shizune.co/investors/profile/boehringer-ingelheim-venture-fund) — VC Fund, 2 deals together
- [OCCIDENT](https://shizune.co/investors/profile/occident-group) — VC Fund, 2 deals together

## About coparion

VC Fund · Cologne, Germany

Coparion provides venture capital to accelerate momentum and growth. With a currently active fund of EUR 275 million, Coparion has the means to do so.Coparion supports entrepreneurial vision with know-how, but without intervening in daily business operations. Thanks to in-depth experience in venture capital and in building companies, the Coparionteam discerns potential and opens up new perspectives. Coparion has the substance, tenacity, and creativity required to mutually manage difficult situations successfully.Coparion only invests with co-investors. The fund invests up to EUR 15M per company, usually in several financing rounds of EUR 0.5-8M each. The investment focus is on German companies in the start-up and early growth phases. Coparion is based in Cologne and Berlin.

5 contacts available at coparion.

| Name | Title | Profile |
| --- | --- | --- |
| David Zimmer | Managing Director | https://shizune.co/investors/profile/david-zimmer |
| Felix Raasch | Senior Investment Associate | https://shizune.co/investors/profile/felix-raasch |
| Sebastian Pünzeler | Principal | https://shizune.co/investors/profile/sebastian-p%C3%BCnzeler |
| Stefan Martinez | Venture Capital Investment Manager | https://shizune.co/investors/profile/stefan-martinez |
| Vera Mehler | Investment Associate | https://shizune.co/investors/profile/vera-mehler |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Sebastian Pünzeler invest in?

Sebastian Pünzeler invests primarily in Biotechnology, Health Care and Life Science startups, most often at Series A and Seed stage. Most of the 4 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Sebastian Pünzeler last invest?

The most recent investment recorded for Sebastian Pünzeler closed in May 2022. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co